Literature DB >> 17717661

TNM staging with FDG-PET/CT in patients with primary head and neck cancer.

Patrick Veit-Haibach1, Christopher Luczak, Isabel Wanke, Markus Fischer, Thomas Egelhof, Thomas Beyer, Gerlinde Dahmen, Andreas Bockisch, Sandra Rosenbaum, Gerald Antoch.   

Abstract

PURPOSE: PET/CT, PET+CT, and CT were compared concerning accuracies in TNM staging and malignancy detection in head and neck cancer. The impact of PET/CT compared to the other imaging modalities on therapy management was assessed.
MATERIALS AND METHODS: Fifty-five patients with suspected head and neck primary cancer underwent whole-body FDG-PET/CT. PET/CT and PET+CT were evaluated by a nuclear medicine physician and a radiologist; CT was evaluated by two radiologists, PET by two nuclear physicians. Histopathology served as the standard of reference. Differences between the staging modalities were tested for statistical significance by McNemar's test.
RESULTS: Overall TNM-staging and T-staging with PET/CT were more accurate than PET+CT and CT alone (p < 0.05). PET/CT was marginally more accurate than CT alone in N-staging (p = 0.04); no statistically significant difference was found when compared to PET+CT for N-staging. PET/CT altered further treatment in 13 patients compared to CT only and in 7 patients compared to PET+CT.
CONCLUSION: Combined PET/CT proved to be partly more accurate in assessing the overall TNM-stage than CT and PET+CT. These results were based on a higher accuracy concerning the T-stage, mainly in patients with metallic implants and marginally the N-stage. Therapy decisions have been influenced in a substantial number of patients. PET/CT might be considered as a first line diagnostic tool in patients with suspected primary head and neck cancer.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17717661     DOI: 10.1007/s00259-007-0564-5

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN: 1619-7070            Impact factor:   9.236


  34 in total

1.  Positron emission tomography and PET CT of the head and neck: FDG uptake in normal anatomy, in benign lesions, and in changes resulting from treatment.

Authors:  Gerhard W Goerres; Gustav K Von Schulthess; Thomas F Hany
Journal:  AJR Am J Roentgenol       Date:  2002-11       Impact factor: 3.959

2.  The role of positron emission tomography and computed tomography fusion in the management of early-stage and advanced-stage primary head and neck squamous cell carcinoma.

Authors:  Patrick K Ha; Alia Hdeib; David Goldenberg; Heather Jacene; Pavni Patel; Wayne Koch; Joseph Califano; Charles W Cummings; Paul W Flint; Richard Wahl; Ralph P Tufano
Journal:  Arch Otolaryngol Head Neck Surg       Date:  2006-01

Review 3.  Head and neck lesions. Radiologic-pathologic correlations.

Authors:  D M Yousem; K T Montone
Journal:  Radiol Clin North Am       Date:  1998-09       Impact factor: 2.303

4.  18F-FDG PET/CT for detecting nodal metastases in patients with oral cancer staged N0 by clinical examination and CT/MRI.

Authors:  Heiko Schöder; Diane L Carlson; Dennis H Kraus; Hilda E Stambuk; Mithat Gönen; Yusuf E Erdi; Henry W D Yeung; Andrew G Huvos; Jatin P Shah; Steven M Larson; Richard J Wong
Journal:  J Nucl Med       Date:  2006-05       Impact factor: 10.057

5.  Cancer statistics, 2005.

Authors:  Ahmedin Jemal; Taylor Murray; Elizabeth Ward; Alicia Samuels; Ram C Tiwari; Asma Ghafoor; Eric J Feuer; Michael J Thun
Journal:  CA Cancer J Clin       Date:  2005 Jan-Feb       Impact factor: 508.702

6.  Normal FDG distribution patterns in the head and neck: PET/CT evaluation.

Authors:  Yuji Nakamoto; Mitsuaki Tatsumi; Dima Hammoud; Christian Cohade; Medhat M Osman; Richard L Wahl
Journal:  Radiology       Date:  2005-03       Impact factor: 11.105

7.  Potential novel application of dual time point SUV measurements as a predictor of survival in head and neck cancer.

Authors:  Bal Sanghera; Wai Lup Wong; Martin A Lodge; Sharon Hain; David Stott; John Lowe; Catherine Lemon; Kate Goodchild; Michele Saunders
Journal:  Nucl Med Commun       Date:  2005-10       Impact factor: 1.690

8.  Unknown primary tumors: detection with dual-modality PET/CT--initial experience.

Authors:  Andreas Gutzeit; Gerald Antoch; Hilmar Kühl; Thomas Egelhof; Markus Fischer; Elke Hauth; Susanne Goehde; Andreas Bockisch; Jörg Debatin; Lutz Freudenberg
Journal:  Radiology       Date:  2004-11-24       Impact factor: 11.105

9.  18F-FDG PET definition of gross tumor volume for radiotherapy of non-small cell lung cancer: is a single standardized uptake value threshold approach appropriate?

Authors:  Kenneth J Biehl; Feng-Ming Kong; Farrokh Dehdashti; Jian-Yue Jin; Sasa Mutic; Issam El Naqa; Barry A Siegel; Jeffrey D Bradley
Journal:  J Nucl Med       Date:  2006-11       Impact factor: 10.057

Review 10.  Recent advances in head and neck cancer therapy: the role of new cytotoxic and molecular-targeted agents.

Authors:  Francesco Caponigro; Amalia Milano; Maria Basile; Franco Ionna; Rosario Vincenzo Iaffaioli
Journal:  Curr Opin Oncol       Date:  2006-05       Impact factor: 3.645

View more
  20 in total

1.  Virtual 3-D ¹⁸F-FDG PET/CT panendoscopy for assessment of the upper airways of head and neck cancer patients: a feasibility study.

Authors:  Christian Buchbender; Jon Treffert; Götz Lehnerdt; Stefan Mattheis; Bernhard Geiger; Andreas Bockisch; Michael Forsting; Gerald Antoch; Till A Heusner
Journal:  Eur J Nucl Med Mol Imaging       Date:  2012-06-05       Impact factor: 9.236

2.  Combined PET/CT-perfusion in patients with head and neck cancers.

Authors:  Patrick Veit-Haibach; Daniel Schmid; Klaus Strobel; Jan D Soyka; Niklaus G Schaefer; Stephan K Haerle; Gerhard Huber; Gabriele Studer; Burkhardt Seifert; Thomas F Hany
Journal:  Eur Radiol       Date:  2012-07-08       Impact factor: 5.315

Review 3.  Present and future role of FDG-PET/CT imaging in the management of head and neck carcinoma.

Authors:  Kazuhiro Kitajima; Yuko Suenaga; Kazuro Sugimura
Journal:  Jpn J Radiol       Date:  2015-10-27       Impact factor: 2.374

Review 4.  Opportunities and challenges facing biomarker development for personalized head and neck cancer treatment.

Authors:  Alexandra Lucs; Benjamin Saltman; Christine H Chung; Bettie M Steinberg; David L Schwartz
Journal:  Head Neck       Date:  2012-01-27       Impact factor: 3.147

5.  Multicenter Trial of [18F]fluorodeoxyglucose Positron Emission Tomography/Computed Tomography Staging of Head and Neck Cancer and Negative Predictive Value and Surgical Impact in the N0 Neck: Results From ACRIN 6685.

Authors:  Val J Lowe; Fenghai Duan; Rathan M Subramaniam; JoRean D Sicks; Justin Romanoff; Twyla Bartel; Jian Q Michael Yu; Brian Nussenbaum; Jeremy Richmon; Charles D Arnold; David Cognetti; Brendan C Stack
Journal:  J Clin Oncol       Date:  2019-02-15       Impact factor: 44.544

Review 6.  PET-MR imaging using a tri-modality PET/CT-MR system with a dedicated shuttle in clinical routine.

Authors:  Patrick Veit-Haibach; Felix Pierre Kuhn; Florian Wiesinger; Gaspar Delso; Gustav von Schulthess
Journal:  MAGMA       Date:  2012-10-09       Impact factor: 2.310

7.  Metabolic tumor volume as a prognostic imaging-based biomarker for head-and-neck cancer: pilot results from Radiation Therapy Oncology Group protocol 0522.

Authors:  David L Schwartz; Jonathan Harris; Min Yao; David I Rosenthal; Adam Opanowski; Anthony Levering; K Kian Ang; Andy M Trotti; Adam S Garden; Christopher U Jones; Paul Harari; Robert Foote; John Holland; Qiang Zhang; Quynh-Thu Le
Journal:  Int J Radiat Oncol Biol Phys       Date:  2015-03-15       Impact factor: 7.038

8.  18F-FDG PET/CT-based gross tumor volume definition for radiotherapy in head and neck cancer: a correlation study between suitable uptake value threshold and tumor parameters.

Authors:  Chia-Hung Kao; Te-Chun Hsieh; Chun-Yen Yu; Kuo-Yang Yen; Shih-Neng Yang; Yao-Ching Wang; Ji-An Liang; Chun-Ru Chien; Shang-Wen Chen
Journal:  Radiat Oncol       Date:  2010-09-02       Impact factor: 3.481

9.  The Value of F-18 FDG PET for Planning Treatment and Detecting Recurrence in Malignant Salivary Gland Tumors: Comparison with Conventional Imaging Studies.

Authors:  Hye Lim Park; Ie Ryung Yoo; Narae Lee; Hyukjin Yoon; Eun Kyoung Choi; Hyun Su Choi; Sung Hoon Kim
Journal:  Nucl Med Mol Imaging       Date:  2013-08-21

10.  Staging primary head and neck cancers with (18)F-FDG PET/CT: is intravenous contrast administration really necessary?

Authors:  Keisuke Yoshida; Akiko Suzuki; Toshiyuki Nagashima; Jin Lee; Choichi Horiuchi; Mamoru Tsukuda; Tomio Inoue
Journal:  Eur J Nucl Med Mol Imaging       Date:  2009-04-08       Impact factor: 9.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.